Follicular lymphoma develops if one’s body makes abnormal B-lymphocytes in lymph nodes. It is the second most common indolent non-Hodgkin’s lymphoma. Night sweats, weight loss, enlargement of lymph nodes in groin, neck and abdomen, fatigue and difficulties in breathing are a few symptoms of follicular lymphoma. Blood tests, X-rays and biopsy are used to diagnose follicular lymphoma. A few other treatment options available to treat this condition include stem cell transplant, chemotherapy, targeted therapy and radiation therapy.
View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/follicular-lymphoma-treatment-market/
There are several factors that are expected to foster the growth of the follicular lymphoma treatment market such as technological developments in disease diagnosis techniques, increasing occurrence of follicular lymphoma, growing research and development activities to innovate novel drugs and family blood disorders. In addition, initiatives taken by government for the management of this disease, promising pipeline products and innovation of novel therapies like monoclonal antibodies are anticipated to drive the follicular lymphoma treatment market over the forecast period 2021-2027. On the other hand, unfavorable effects associated with the treatment, strict regulatory policies for the approval of drug and the high price of treatment are the factor anticipated to hinder the follicular lymphoma treatment market.
Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma
Request sample report https://precisionbusinessinsights.com/request-sample?product_id=18854
Global follicular lymphoma treatment market is classified into different major regions such as North America, Latin America, Europe, Middle East, Africa and Asia Pacific. North America is anticipated to grow at significant rate owing to the factors such as growing R&D activities to innovate new drugs and growing healthcare expenses in the region. Follicular lymphoma treatment market in Europe is anticipated to experience significant growth because of increasing cases of follicular lymphoma because of changing lifestyle, huge adoption of novel therapies and sophisticated healthcare infrastructure in the region. Asia Pacific market is also witnessing profitable growth due to the factors such as huge patient pool and growing awareness about lymphoma treatment. Follicular lymphoma treatment market in Latin America is anticipated to record moderate growth because of the economic growth in the region, business expansion by key players and adoption of novel drugs in the region.
Major Key players operating in the follicular lymphoma treatment market are Hoffmann La Roche Ltd. (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline plc (U.K.), Merck & Co. Inc. (U.S.), AbbVie, Inc. (U.S.), Bayer AG (Germany), Epizyme Inc. (U.S.), Bristol Myers Squibb (U.S.) and Johnson and Johnson Services Inc. (U.S.).
About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.
Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747